Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
GammaDelta Therapeutics logo — GammaDelta Therapeutics focuses on using γδ T cells to impro...

GammaDelta Therapeutics

GammaDelta Therapeutics focuses on using γδ T cells to improve survival rates of patients with cancer.

Founded 2016 United Kingdom London, United Kingdom 4 employees Seed Biotechnology, Health Care +1

General Information

Company Name GammaDelta Therapeutics
Founded Year 2016
Location United Kingdom London, United Kingdom +1
Founders / Decision Makers
Team member
Employees 4
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Seed
Social

Get notified when GammaDelta Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About GammaDelta Therapeutics

GammaDelta Therapeutics is a UK-based biotechnology startup founded in 2016 by Professor Adrian Hayday and Dr. Oliver Nussbaumer, with support from Cancer Research Technology. The company's mission is to leverage the unique properties of γδ T cells to improve patient outcomes and survival rates in the treatment of haematological malignancies and solid tumors. GammaDelta aims to deliver highly effective allogeneic immunotherapies based on the unique properties of Vδ1+ T cells, with the potential to provide additional benefits towards patient survival. The proprietary isolation and expansion protocols have the ability to selectively generate Vδ1+ T cell populations suitable for clinical application. The company's technologies are based on pioneering research conducted by Professor Adrian Hayday and Dr. Oliver Nussbaumer at King’s College London and the Francis Crick Institute, as well as Professor Bruno Silva-Santos at the University of Lisbon. GammaDelta's innovative approach has garnered recognition for its therapeutic potential, attracting interest from the pharmaceutical industry and investments from Takeda Pharmaceutical Company Limited and Abingworth LLP. The last recorded investment was a Seed Round investment on 16 September 2016, with key investors including Abingworth, King's College London, Cancer Research Technology, and The Francis Crick Institute. With its focus on cutting-edge biotechnology and healthcare, GammaDelta Therapeutics stands at the forefront of advancing innovative immunotherapies for cancer treatment.

Taxonomy: immunotherapy, cancer treatment, T-cell therapy, oncology, immunology, cell therapy, academic research, investments, clinical application, allogeneic immunotherapies, solid tumors, hematological malignancies, pharmaceutical industry, tissue resident T cells

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round •••••• 4
Investor Investor
•••• •••• 		16 Sep 2016

FAQ About GammaDelta Therapeutics

GammaDelta Therapeutics focuses on using γδ T cells to improve survival rates of patients with cancer.
GammaDelta Therapeutics was founded in 2016.
GammaDelta Therapeutics is headquartered in London, United Kingdom.
GammaDelta Therapeutics operates in the following industries: Biotechnology, Health Care, Health and Wellness.
GammaDelta Therapeutics has approximately 4 employees.
GammaDelta Therapeutics has completed 1 funding round. The latest funding stage is Seed.

We're actively collecting intelligence on GammaDelta Therapeutics.

Track GammaDelta Therapeutics to get notified

Don't just browse. Track.

Signal Tracker monitors GammaDelta Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy